All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, August 11, 2022
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Nonprofit stamp

Infection tops nonprofit deal efforts; U.S. covers 57% of grants

June 24, 2022
By Karen Carey
No Comments
Nonprofit deals with biopharma companies in 2022 indicate that 92% of the disclosed funds are going toward infectious disease therapies, with COVID-19 accounting for 79% of the total.
Read More
Financial chart

Biopharma index down, but doing better than most

June 22, 2022
By Karen Carey
No Comments
While BioWorld’s Biopharmaceutical Index remains down slightly from the end of last year, recent gains by several companies suggest the industry may be beginning to bounce back.
Read More
Digital handshake

Strong dealmaking dominated by Sanofi, BMS

June 20, 2022
By Karen Carey
No Comments
While Pfizer Inc. remains active with mergers and acquisitions, Sanofi SA and Bristol Myers Squibb Co. are major players in the top six biopharma deals of 2022. So far this year, the industry has announced 769 deals, including licensings, joint ventures and collaborations, valued at $88.9 billion.
Read More

Biggest gainers and losers for the week of June 13-17, 2022

June 17, 2022
No Comments
The top 10 biopharma stock gainers and losers for the week.
Read More

Biopharma money raised: Jan. 1-June 16, 2022

June 17, 2022
No Comments
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2022 vs. 2021 vs. 2020 vs. 2019

June 17, 2022
No Comments
Total raised in public, private and other financings of biopharma companies, comparing 2022 vs. 2021 vs. 2020 vs. 2019.
Read More
Viruses

Infectious disease firms struggle in market downcycle

June 16, 2022
By Karen Carey
No Comments
In sharp contrast with its up and down rhythm of 2021, the BioWorld Infectious Disease Index (BIDI) is mostly down this year, having fallen 63.4% to date. The index ended last year up by 10.4%, which was its lowest point. In 2020, when the SARS-CoV-2 infection became a global focus, BIDI was up by 144%.
Read More

Med-tech gainers and losers for June 13-17, 2022

June 13, 2022
No Comments
The top 10 med-tech stock gainers and losers for the week.
Read More
Global currency

VC rounds nearly half of all biopharma money raised

June 13, 2022
By Karen Carey
No Comments
Venture capital remains the primary driver of biopharma financings in 2022, accounting for 48.7% of all financings for the year. That is dramatically more than 2021 when 31% of the money raised by this point came through VC rounds. In 2020, the amount was only 18%.
Read More
Digital stock chart

Drug developer stocks three times lower than 2021

June 13, 2022
By Karen Carey
No Comments
After a sharp drop in April, BioWorld’s Drug Developers Index is beginning to rise, although it is not yet showing what many investors would like to see, and it remains at one of its lowest points in 18 months.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 … 135 136 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 10, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 10, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing